Merck, Samsung Accelerate a Biosimilar Price War – Bloomberg

Merck, Samsung Accelerate a Biosimilar Price War – Bloomberg

Bloomberg

Merck, Samsung Accelerate a Biosimilar Price War
Bloomberg
Back in November, when Pfizer Inc. launched its biosimilar — a generic version of a drug made with living cells — of Johnson & Johnson's blockbuster inflammation drug Remicade, it priced the copy at just a 15 percent discount to the original's list
Merck, Samsung Bioepis launch discounted US Remicade alternativeReuters


A cheaper version of a blockbuster drug just launched at a 35% discount — and it could save the US billionsBusiness Insider
(infliximab-abda) Now Available in the United StatesBusiness Wire (press release)
Wall Street Journal (subscription) –Genetic Engineering & Biotechnology News –Philadelphia Business Journal –UPI.com
all 22 news articles »

0
Like
Save

Comments

Comments are disabled for this post.